ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is trading at $2.24 up 1.82%. Investors Capital Holdings Ltd (NYSEMKT:ICH) is trading at $4.68 up 3.77%.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is trading at $2.228 up 1.74%. New Gold Inc. (USA) (NYSEMKT:NGD) is trading at $6.685 down -0.22%.

ALLENDALE, N.J. and LOS ANGELES, June 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), its subsidiary, Progenitor Cell Therapy LLC ("PCT"), and ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC) ("IMUC"), a clinical-stage ...

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed ...

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in ...

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on ...

Guess?, Inc. (NYSE:GES) is trading at $30.66 down -0.42%. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is trading at $2.27 down -1.3%.

The phase II clinical trials of the ICT - 107 developed by ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) had been subject to a pre specified interim analysis by the Data monitoring committee following which the committee had recommended the ...

In most recent news, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the US Food and Drug Administration has allowed the investigation on new drug (IND) application for ICT-140, making ways for conducting a clinical trial.

ImmunoCellular Therapeutics Ltd logo Stock analysts at MLV Capital boosted their price objective on shares of ImmunoCellular Therapeutics Ltd (NASDAQ: IMUC) from $5.00 to $6.00 in a report issued on Friday, Analyst Ratings Network.com reports.